GlassScriptPhysician profile
Elizabeth C Flaherty
NPI 1881907699
$10,259.16
in general payments reported to CMS, 2019-2025
44 companies · $2,440 in 2025
The $2,440 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,272 · 2020: $754 · 2021: $1,898 · 2022: $1,183 · 2023: $1,262 · 2024: $1,450 · 2025: $2,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,152.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,706.91 | 2021-2025 | |
| Pfizer INC. | $1,180.58 | 2023-2025 | |
| Ucb, INC. | $544.91 | 2019-2025 | Briviact, Zilbrysq |
| Tg Therapeutics, INC. | $475.99 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $452.28 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $431.60 | 2019-2025 | Austedo Xr, Ajovy |
| Biohaven Pharmaceuticals, INC. | $413.66 | 2021 | |
| Lilly USA, LLC | $393.12 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Supernus Pharmaceuticals, INC. | $334.83 | 2019-2025 | Qelbree |
| Novartis Pharmaceuticals Corporation | $326.49 | 2019-2021 | |
| Allergan, INC. | $309.98 | 2019-2022 | |
| Argenx US, INC. | $241.30 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Medtronic USA, INC. | $202.68 | 2019-2020 | |
| Amgen INC. | $180.81 | 2020-2022 | |
| Lundbeck LLC | $178.30 | 2019-2025 | Vyepti |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Flaherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.